Changes in Hong Kong stocks | Hengrui Pharmaceutical (01276) rose more than 6% in the afternoon. The company expects more than 40 listing applications to be approved in the next two years

The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose more than 6% in the afternoon. As of press release, it rose 6.05% to HK$49.06, with a turnover of HK$315 million.

According to the news, recently, the US “Pharmaceutical Manager” magazine published the “2026 Top 50 Global Pharmaceutical Companies” list. Hengrui Pharmaceutical, an innovation-driven international pharmaceutical company, is once again on the list. The company has been on this list for eight consecutive years since 2019. PharmExec is a well-known pharmaceutical magazine in the international pharmaceutical industry. This year, it is the 26th time that it has launched the TOP50 list of global pharmaceutical companies.

Notably, Hengrui Pharmaceutical stated at the 2026 semi-annual results briefing on September 10 that it is expected that more than 40 marketing applications will be approved from 2027 to 2028, covering 5 major treatment fields. Among them, potential major products include SHR-A2009, the first single-target HER3 ADC drug to be declared for marketing in China.